---
document_datetime: 2025-12-29 18:59:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-ditromethamine-hospira.html
document_name: pemetrexed-ditromethamine-hospira.html
version: success
processing_time: 0.0872126
conversion_datetime: 2025-12-30 10:23:38.240097
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pemetrexed ditromethamine Hospira

[RSS](/en/individual-human-medicine.xml/65575)

##### Application withdrawn

The application for this medicine has been withdrawn

pemetrexed Medicine Human Application withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [News on Pemetrexed ditromethamine Hospira](#news-on)
- [Related information](#related-information-62295)
- [More information on Pemetrexed ditromethamine Hospira](#more-information-on-pemetrexed-ditromethamine-hospira-62319)
- [Topics](#topics)

- Application under evaluation
- Withdrawal of application

## Overview

On 22 September 2016, Hospira UK Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Pemetrexed (as ditromethamine) Hospira, for the treatment of malignant pleural mesothelioma and non-small-cell lung cancer.

Expand section

Collapse section

## What is Pemetrexed (as ditromethamine) Hospira?

Pemetrexed (as ditromethamine) Hospira is a cancer medicine that contains the active substance pemetrexed. It was to be available as a powder to be made up into a solution for infusion (drip) into a vein.

Pemetrexed (as ditromethamine) Hospira was developed as a 'generic medicine'. This means that it was intended to be similar to a 'reference medicine' already authorised in the European Union called Alimta. For more information on generic medicines.

## What was Pemetrexed (as ditromethamine) Hospira expected to be used for?

Pemetrexed (as ditromethamine) Hospira was expected to be used to treat two types of lung cancer: malignant pleural mesothelioma (a cancer of the lining of the lungs usually caused by exposure to asbestos) and advanced non-small-cell lung cancer of the kind known as 'non-squamous'.

## How does Pemetrexed (as ditromethamine) Hospira work?

Pemetrexed (as ditromethamine) Hospira is expected to work in the same way as the reference medicine, Alimta. The active substance in both medicines, pemetrexed, is changed in the body into an active form that blocks enzymes needed to make genetic material (DNA and RNA). The change into an active form happens more readily in cancer cells than in normal cells. This prevents the cancer cells from growing and dividing, while normal cells are only slightly affected.

## What did the company present to support its application?

Because Pemetrexed (as ditromethamine) Hospira was developed as a generic medicine, the company presented the results of studies to show the quality of the medicine. No further studies were carried out because Pemetrexed (as ditromethamine) Hospira is a generic medicine that is given by infusion into a vein and contains the same active substance as the reference medicine, Alimta.

## How far into the evaluation was the application when it was withdrawn?

The application was withdrawn after the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions. The company had not yet responded to the questions at the time of the withdrawal.

## What was the recommendation of the CHMP at that time?

Based on the review of the data at the time of the withdrawal, the CHMP had asked the company to provide clarification on some aspects of manufacturing, storage and plans to monitor safety and effectiveness of the medicine after authorisation. The CHMP thought that the company could have addressed these questions and was of the provisional opinion that Pemetrexed (as ditromethamine) Hospira could have been approved for the treatment of malignant pleural mesothelioma and non-small-cell lung cancer.

## What were the reasons given by the company for withdrawing the application?

In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing its application because of a change in commercial strategy.

## What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?

The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for this product.

Questions and answers on the withdrawal of the marketing authorisation application for Pemetrexed ditromethamine Hospira

Reference Number: EMA/659373/2016

English (EN) (74.88 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_en.pdf)

[Other languages (22)](#file-language-dropdown-875)

български (BG) (95.12 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/bg/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_bg.pdf)

español (ES) (67.4 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/es/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_es.pdf)

čeština (CS) (91.49 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/cs/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_cs.pdf)

dansk (DA) (67.46 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/da/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_da.pdf)

Deutsch (DE) (67.5 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/de/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_de.pdf)

eesti keel (ET) (66.34 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/et/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_et.pdf)

ελληνικά (EL) (96.37 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/el/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_el.pdf)

français (FR) (67.52 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/fr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_fr.pdf)

hrvatski (HR) (100.73 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/hr/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_hr.pdf)

italiano (IT) (67.32 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/it/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_it.pdf)

latviešu valoda (LV) (86.7 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/lv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_lv.pdf)

lietuvių kalba (LT) (88.51 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/lt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_lt.pdf)

magyar (HU) (84.98 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/hu/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_hu.pdf)

Malti (MT) (91.85 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/mt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_mt.pdf)

Nederlands (NL) (67.39 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/nl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_nl.pdf)

polski (PL) (90.6 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/pl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_pl.pdf)

português (PT) (67.48 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/pt/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_pt.pdf)

română (RO) (87.34 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/ro/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_ro.pdf)

slovenčina (SK) (117.49 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/sk/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sk.pdf)

slovenščina (SL) (83.94 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/sl/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sl.pdf)

Suomi (FI) (66.68 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/fi/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_fi.pdf)

svenska (SV) (67.95 KB - PDF)

**First published:**

14/10/2016

**Last updated:**

14/10/2016

[View](/sv/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-pemetrexed-ditromethamine-hospira_sv.pdf)

## Key facts

Name of medicine Pemetrexed ditromethamine Hospira Active substance pemetrexed ditromethamine International non-proprietary name (INN) or common name pemetrexed Therapeutic area (MeSH)

- Mesothelioma
- Carcinoma, Non-Small-Cell Lung

Anatomical therapeutic chemical (ATC) code L01BA04 EMA product number EMEA/H/C/004306

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Withdrawal of application 22/09/2016

## All documents

Withdrawal assessment report for Pemetrexed ditromethamine Hospira

Adopted

Reference Number: EMA/CHMP/485042/2016

English (EN) (165.84 KB - PDF)

**First published:** 21/12/2016

**Last updated:** 21/12/2016

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-pemetrexed-ditromethamine-hospira_en.pdf)

Withdrawal letter: Pemetrexed ditromethamine Hospira

English (EN) (1.24 MB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/withdrawal-letter/withdrawal-letter-pemetrexed-ditromethamine-hospira_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### News on Pemetrexed ditromethamine Hospira

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-3&p_p_col_count=2&folderName=EMEAHC0043060000) (marketing authorisation application)

#### More information on Pemetrexed ditromethamine Hospira

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/12/2016

## Share this page

[Back to top](#main-content)